Self-aggregates of low density lipoprotein (LDL) are taken up and degraded more rapidly by macrophages than is native LDL. That enhanced uptake is attributable in part to phagocytosis via the LDL receptor pathway. However, arterial macrophages appear to express little LDL receptor activity. The present studies demonstrate an alternative mechanism by which LDL aggregates could contribute to foam cell formation. This could occur by the formation of large immune complexes that are taken up by macrophages via the F c receptor. When immune complexes were formed with native, soluble LDL and MB47, a monoclonal antibody specific to the apoprotein B domain recognized by the LDL receptor, the subsequent uptake and degradation of the LDL by macrophages were inhibited 50-80% compared with native LDL alone. In contrast, when aggregated LDL was bound to MB47 at a similar molar ratio, the subsequent degradation of the insoluble immune complexes was two-to fivefold greater than that of aggregated LDL alone. The enhanced uptake was abolished when Fab or F(ab'>2 fragments of MB47 were substituted for the intact antibody, indicating that the increased uptake was via the F c receptor pathway. Furthermore, the uptake of the immune complexes of aggregated LDL was reduced by competition for the that self-aggregates of low density lipoprotein (LDL) produced by vortexing (Vx-LDL) were taken up and degraded by cultured macrophages much more rapidly than monomeric native LDL.
In cell culture, the LDL receptor activity of monocyte-derived macrophages is downregulated by exposure to serum or LDL. Although monocytes that have recently entered the intima may still express LDL receptor activity, under conditions of marked hypercholesterolemia or in advanced lesions, arterial macrophages appear to express little or no LDL receptor mRNA. 5 Thus, for LDL aggregates to continue to contribute importantly to macrophage accumulation of cholesterol under these conditions, an alternative pathway for macrophage uptake may be needed. Antibody-antigen complexes are taken up by macrophages via the F c receptor pathway, and this should not be downregulated as a result of cholesterol loading. Although soluble antigen-antibody complexes bind readily to F c receptors on macrophages, large, insoluble, multimeric complexes are required for high-affinity binding and rapid internalization.
We now report that a model system of LDL aggregates complexed with monoclonal antibodies against LDL are taken up and degraded by macrophages twoto fivefold faster than uncomplexed aggregates of LDL. Moreover, this uptake is phagocytic, being mediated by the F c receptor via the zipper mechanism. 6 Since aggregates of LDL and modified LDL are likely to occur in the intima and autoantibodies to epitopes of modified LDL are present in plasma, 7 -11 the formation of such by guest on April 2, 2017 http://atvb.ahajournals.org/ Downloaded from immune complexes may provide an additional pathway for macrophage uptake of LDL and could play a role in accelerating cholesteryl ester accumulation.
Methods

Cells
Mouse peritoneal macrophages were elicited by intraperitoneal injection of 2 ml thioglycollate medium (DIFCO) 3 days before harvest. For degradation and esterification assays, macrophages were plated in 24-well clustered dishes (lxlO 6 cells per well) in Iscove's modified Dulbecco's medium (IMDM) (GIBCO) containing 10% fetal bovine serum. For experiments in which cellular cholesterol mass was measured, six-well clustered dishes were used (4xlO 6 cells per well). Two hours after plating, nonadherent cells were removed by washing with phosphate-buffered saline (PBS). The cells were then incubated overnight at 37°C in IMDM containing 5 mg/ml lipoprotein-deficient serum (LPDS).
Lipoproteins
LDL (d=1.019-1.063 g/1) and LPDS (d> 1.215 g/1) were isolated by preparative ultracentrifugation from fresh human plasma as described previously. 1 LDL was radioiodinated by the method of Salacinski et al. 12 Vx-LDL was prepared by vortexing LDL (0.5 mg protein/ml PBS) for 60 seconds as previously described, 1 and PLC-LDL was produced by incubating LDL (0.25 mg protein/ml PBS) with 1 unit/ml phospholipase C (type XI, from Bacillus cereus; Sigma) at 37°C for 1 hour. 2 
Antibodies
Protein A-purified apoprotein (apo) B-specific monoclonal antibodies MB47 13 and MB24 14 against LDL were generously provided by Dr. Richard S. Smith from Johnson and Johnson Biotechnology Center, La Jolla, Calif. Both MB47 and MB24 were identified by double immunodiffusion as immunoglobulin G 2a (IgG 2a ) . 13>14 A control mouse immunoglobulin (IgG 2a ) was purchased from Calbiochem Corp. Fab fragments of MB47 were prepared as previously described by digestion with immobilized papain, followed by chromatography on a column of immobilized protein A-agarose (Pierce) to remove the F c portion.
13 F(ab') 2 fragments of MB47 were prepared by using the Pierce Immunopure F(ab') 2 kit. The MB47 was digested with immobilized pepsin and separated on an immobilized protein A-agarose column. One-milliliter fractions were collected, and absorbance was measured at 280 nm. The fractions containing F(ab') 2 fragments were combined and concentrated to a final volume of 1 ml in a Centricon 10 microconcentrator (Amicon). Products were verified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Heat-aggregated IgG was prepared by heating the control mouse IgG (20 mg/ml) at 63°C for 20 minutes, according to the method described by Griffith et al. 15 
Preparation of LDL-Immune Complexes
LDL-immune complexes were prepared by incubating monomeric native LDL, Vx-LDL, or PLC-LDL with the indicated concentration of antibody for 16 hours at 4°C. The molar ratios were calculated by assuming a molecular mass for apo B of 550 kd, for monoclonal and control IgG of 166 kd, for Fab fragments of 40 kd, and for F(ab') 2 fragments of 105 kd. The ability of MB47 and its Fab or F(ab') 2 fragments to inhibit the degradation of LDL by human skin fibroblasts was measured as described 13 by using cells grown to near confluency on 24-well clustered dishes that were incubated overnight in 5 mg/ml LPDS before the addition of soluble LDL-MB47 complexes.
Other Methods
The degradation of 125 I-LDL by cells was determined using methods described by Goldstein et al. 16 Each monolayer of thioglycollate-elicited mouse peritoneal macrophages received 0.5 ml IMDM containing 5 mg/ml LPDS and the indicated concentration of 125 I-LDL protein. After incubation for the specified time at 37°C, the medium was removed. The amount of apo B degraded was determined by the 125 I-trichloroacetic acid (TCA)-soluble (noniodide) material present in the medium. The cells were washed with PBS and treated with 0.1% trypsin in saline to remove LDL bound to the surface of macrophages. The types of aggregated LDL used for the various experiments did not adhere to the plastic dishes. The remaining cells were solublized in 0.2 M NaOH, and aliquots were removed for counting as well as for protein determination by the method of Lowry et al. 17 For these studies we have defined the amount of 125 I released from the cells by trypsin as "bound," the total amount of 125 I remaining in the cells at the end of the trypsinization as "cell content," and the amount of noniodide TCA-soluble material present in the medium as amount "degraded." "Total uptake" was defined as the sum of bound plus cell content plus amount degraded.
To measure the effect of heat-aggregated IgG to compete for the degradation of LDL-immune complexes, a 200-fold protein excess of the aggregated IgG was added to the cell monolayers 1 hour before the addition of the 125 I-LDL. 16 Briefly, the indicated concentrations of LDL protein/ml IMDM, containing 5 mg/ml LPDS, were incubated with mouse peritoneal macrophages for 6 hours at 37°C. One hour before harvest, 0.2 mM [ 14 C]oleate/albumin (11,000 dpm/nmol) was added to each well. The monolayers were washed with PBS, and the total lipid was extracted in situ. To measure cellular sterol content, macrophage monolayers on 35-mm culture dishes were incubated with 25-100 fig LDL protein/ml medium for 24 hours in serumfree medium. After washing three times with PBS, treating with 0.1% trypsin for 15 minutes at 37°C, and rewashing three times with PBS, the cells were scraped into 1 ml distilled water and sonicated for 20 seconds. Aliquots were removed for protein determination, and the remainder was extracted for total lipids by the method of Folch et al. 18 The mass of total and free cholesterol was determined by the enzymatic/fluorometric method of Gamble et al.
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Results
The monoclonal antibody MB47 has been shown to bind to the LDL receptor-binding domain of apo B. When native, monomeric 125 I-LDL was preincubated with increasing concentrations of MB47 for 16 hours at 4°C, the subsequent degradation of that LDL by human skin fibroblasts decreased progressively (Figure 1 ), consistent with the earlier findings of Young et al. 13 When the molar ratio of antibody to apo B reached 1:1, uptake was reduced by about 80%. Under the same conditions, the degradation of 125 I-LDL preincubated with a nonspecific IgG was decreased by only 15%.
Mouse peritoneal macrophages take up native LDL at a relatively low rate. To determine the effect of MB47 on the uptake of native LDL by these cells, 125 I-LDL that had been preincubated with MB47 (at a molar ratio of 1:1) was applied to monolayers of thioglycollate-elicited mouse peritoneal macrophages. Although the absolute rate of degradation of the native LDL was low, nevertheless there was a 50% decrease in the degradation in the presence of MB47, indicating that at least 50% of the basal uptake in the macrophages was mediated by the LDL receptor pathway (Figures 2A and 2B ). Control IgG had no effect. In contrast, when MB47 was preincubated with Vx-LDL or PLC-LDL at a 1:1 molar ratio, the degradation of the aggregates was now enhanced fourfold ( Figure 2A ) and 1.7-fold ( Figure 2B ), respectively, over that of aggregated LDL in the absence of antibody. When control IgG was mixed with Vx-LDL at a molar ratio of 1:1, there was a 1.7-fold increase in degradation.
However, this finding was inconsistent, and in general, there was little effect of nonspecific IgG. For example, control IgG had no effect on the degradation of the PLC-LDL at a molar ratio of antibody: apo B of 1:1 and was slightly inhibitory at a molar ratio of 5:1 ( Figure 2B ). Similar results were obtained when either thioglycollateelicited or resident mouse peritoneal macrophages were used (data not shown).
To document that the enhanced uptake of the aggregates bound to MB47 was mediated via the F c receptor pathway, Fab fragments were prepared from the intact MB47. Because Fab fragments generally have a lower affinity for the antigen, we first determined the concentration of MB47 Fab fragments required to inhibit degradation of monomeric 12S I-LDL by human fibroblasts. As shown in Figure 1 , the molar ratio of Fab fragments to apo B required for maximal inhibition of LDL degradation was about 10 times greater than that required with intact MB47. These results were again similar to those of Young et al. 13 Thus a 10-fold molar excess of Fab fragments should yield an immune complex equivalent to that obtained with a 1:1 molar ratio of intact MB47 to LDL. To determine the effect of the MB47 Fab fragments on macrophage uptake of LDL and of aggregated LDL, immune complexes consisting of Fab fragments and LDL were prepared by preincubation at a molar ratio of 20:1 (Fab:apo B). As a control, intact MB47-LDL complexes were also prepared at a molar ratio of 2:1 (MB47:apo B). Intact MB47 decreased macrophage degradation of soluble 125 I-LDL by about 35%; the Fab fragments decreased degradation even more, by about 70% ( Figure 3A) . In contrast, intact MB47 caused an increase in the degradation of Vx-LDL by about threefold, whereas the immune complexes of the Fab fragments and Vx-LDL were degraded to about the same extent as Vx-LDL alone ( Figure 3B ). The results implied that the increased uptake of the immune complex of MB47 plus Vx-LDL over that of the Vx-LDL alone was via the F c receptor pathway.
Because an intact monoclonal antibody has two combining sites, MB47 might cause the formation of larger LDL aggregates when complexed with Vx-LDL, and these complexes might then be taken up by macrophages via a non-F c receptor pathway. Fab fragments of MB47 would not cause further aggregation of the LDL aggregates, since the Fab fragment contains only one of the antibody's binding sites. In contrast, the F(ab') 2 fragment, while lacking the F c portion, contains both of the antibody's binding sites and thus theoretically would lead to the same degree of cross-linking of LDL as would intact MB47, both resulting in an increase in the size of the LDL aggregates. Therefore, F(ab') 2 fragments of MB47 were used to verify that the enhanced uptake of the immune complexes of aggregated LDL was indeed by way of the F c receptor. The stoichiometry of binding of the F(ab') 2 fragment to LDL was determined initially by measuring its ability to inhibit the degradation of soluble l25 I-LDL by human skin fibroblasts ( Figure 1 ). The F(ab') 2 fragment was found to be just as effective as the intact MB47 at identical molar ratios. Immune complexes of intact MB47 or F(ab') 2 fragments of MB47 and LDL, Vx-LDL, or PLC-LDL were prepared by preincubation at 4°C for 16 hours at a molar ratio of 5:1 (antibody: apo B). As shown in Figure  4 , both intact MB47 and F(ab') 2 compete for the uptake and degradation of the immune complexes of Vx-LDL and PLC-LDL. As shown in Figure 4 , macrophage degradation of immune complexes made up of MB47: Vx-LDL or MB47: PLC-LDL was reduced in the presence of the heat-aggregated IgG by 44% and 51%, respectively. The degradation of the Vx-LDL and PLC-LDL was reduced by only 25% and 27%, respectively, in the presence of the heat-aggregated IgG.
The observed increase in uptake and degradation of the immune complexes of MB47 with LDL aggregates resulted in an enhancement in the rate of cholesterol esterification. As shown in Figure 5 , there was a twofold increase in the rate of cholesterol esterification in mouse peritoneal macrophages induced by incubation with immune complexes over that induced by Vx-LDL alone. The enhanced uptake of immune complexes also led to an increased net accumulation of cholesteryl esters (Table 1) . Macrophages incubated for 24 hours with various concentrations of the immune complexes of MB47 and PLC-LDL accumulated 58-76% more cholesteryl esters than did macrophages incubated with PLC-LDL alone.
Monoclonal antibody MB24 is an apo B-specific antibody that binds to the JV-terminal region of apo B and does not interfere with the ability of LDL to bind to the LDL receptor.
14 Immune complexes were prepared with MB24 and soluble LDL, Vx-LDL, and PLC-LDL Phospholipase C-treated (PLC)-low density lipoprotein (LDL) was preincubated alone (-) or in the presence (+) of MB47 at a molar ratio of 1:1 (MB47:apoprotein B) at 4°C. After 16 hours, the aggregates were added to monolayers of mouse peritoneal macrophages for 24 hours at 37°C at the indicated protein concentration. The cells were treated with trypsin to remove bound PLC-LDL before analysis of cholesterol mass. Each point represents the combination of 2x35-mm wells assayed in quadruplicate determinations ±SD.
by preincubations of antibody and LDL at a molar ratio of 2:1 (MB24:apo B) for 16 hours at 4°C. These complexes were subsequently incubated with macrophages for 5 hours at 37°C, and the amounts of LDL degraded and the cell content were determined. As shown in Figure 6A , the presence of MB24 did not inhibit soluble LDL uptake as did MB47 (see Figures 2  and 5 ). Because there is only a single MB47 and a single MB24 binding site on apo B, there can only be a single monoclonal antibody bound to each LDL particle present in either the soluble or aggregated LDL state. Therefore, the presence of MB24 should enhance the rate of degradation of the aggregated LDL similar to that noted with MB47. In fact, the presence of MB24 did stimulate the degradation of Vx-LDL ( Figure 6B ) and PLC-LDL ( Figure 6C ) by 2.5-and 1.9-fold, respectively, similar to that noted with MB47 (compare with Figure 2 ).
The experiment above also suggested that the presence of the antibodies enhanced the ability of macrophages to degrade the LDL internalized (note the increased amount of degraded LDL versus the cell content of LDL). To more fully explore this observation, we determined the kinetics of the binding, internalization, and degradation of monomeric native LDL and of Vx-LDL, alone and in the form of immune complexes. For these experiments, immune complexes were prepared by incubating LDL or Vx-LDL with a mixture of MB47 and MB24 (at equal concentrations) for 16 hours at 4°C. The molar ratio of total antibodies to apo B was 5:1. Equal amounts of I-LDL bound to the surface of cells (i.e., trypsin-releasable cell-associated counts), the cell content (cell-associated counts after trypsinization), and that present in the medium as degradation products were determined, and the results are plotted in Figure  7 . At 2.5 hours, the amount of LDL aggregates bound to the surface of these cells was nearly the same for Vx-LDL and for the Vx-LDL-immune complexes, and both of these were more than eightfold greater than that of native LDL ( Figure 7A ). However, already at 2.5 hours the cell content of LDL presented as Vx-LDLimmune complexes was twice that of Vx-LDL alone ( Figure 7B ), and the degradation of LDL protein was 2.5 times greater than that of Vx-LDL alone ( Figure  7C) . Clearly, the binding, cell content, and degradation were greatest for LDL presented in the form of Vx-LDL-immune complexes. By 7.5 hours, over 80% of LDL protein taken up by the macrophages as Vx-LDLimmune complexes had been degraded compared with only 60% of the LDL protein taken up as Vx-LDL alone ( Figure 7D ). However, by 24 hours, the differences between the two were negligible ( Figure 7C ) as was the difference between the amount of residual LDL protein retained in the cell ( Figure 7B) . After approximately 7.5 hours, there appeared to be a plateauing of the amount of LDL protein degraded when presented as part of Vx-LDL-immune complexes. This probably reflects the more efficient uptake of these immune complexes by the macrophages. In fact, in the experiment shown in Figure 7 , only 2.5 fig LDL protein was presented to the cells. After only 2.5 hours, over 35% of the total LDL protein present in the culture medium in the form of immune complexes had been either bound, internalized, or degraded by the cells while 28% of the Vx-LDL also had been taken up (Figure 8 ). This rapid uptake of the LDL protein from the medium probably led to the rapid decline in apparent binding and plateauing of the amount degraded for the Vx-LDL-immune complexes. Note, however, that the absolute uptake from the media of both Vx-LDL and Vx-LDL-immune complexes greatly exceeded that of native LDL or native LDL complexed with MB47 and MB24 (Figure 8) . Thus, the data in Figure 7 probably represent an underestimate of the capacity of the macrophages to take up and degrade Vx-LDL-immune complexes and to a lesser extent the Vx-LDL alone.
FIGURE 6. Bar graph showing the effect of monoclonal antibody MB24 on the degradation and internalization of low density lipoprotein (LDL), vortexed (Vx)-LDL, and phospholipase C-treated (PLC)-LDL
In the experiment above, only 2.5 ^tg LDL protein was presented to the macrophages. To determine the actual capacity of macrophages to take up LDL when presented as Vx-LDL or as immune complexes of such aggregates, preparations similar to those described in Figure 7 were prepared. Increasing amounts of Vx-LDL and immune complexes of Vx-LDL were incubated with macrophages for 5 hours. As shown in Figure 9 , for the concentrations tested there was a nearly linear increase in the amount of LDL protein bound, internalized, and degraded when presented as immune complexes. Total uptake of the immune complexes was nearly linear, and for all parameters, was greater than that observed for Vx-LDL alone. However, for any given concentration of Vx-LDL added, the presence of the antibodies led to a more efficient rate of cellular degradation ( Figure 9D ).
Discussion
The recent demonstration by Frank, Fogelman, and coworkers 34 that aggregation of LDL does occur in the aortic intima in vivo has renewed interest in the role of LDL aggregation 1 -220 - 26 and immune complexes of LDL 7 -11 ' 27 -31 in atherosclerosis. Our previous studies established that self-aggregates of LDL are themselves taken up more rapidly by macrophages than is native LDL and that the phagocytic uptake of aggregated LDL is mediated in part by the LDL receptor pathway. 1 In vivo, however, when uptake occurs over a protracted period of time, one might anticipate that the LDL receptor would be downregulated. Thus, uptake of LDL aggregates might not continue under in vivo conditions. In addition, under conditions of hypercholesterolemia or as monocytes differentiate into macrophages, LDL receptor activity would decline. 5 Moreover, in patients or WHHL rabbits with a genetic deficiency of the LDL receptor, such a mechanism could not play a role at all. The F c receptor, on the other hand, is not subject to downregulation by these conditions, and uptake by way of that receptor might continue unabated and lead to foam cell formation. The present studies demonstrated that complexes of monoclonal antibodies against LDL with previously prepared aggregates of LDL further increased the already rapid uptake by macrophages of the LDL aggregates. Thus, either MB47, a blocking antibody against the LDL receptor-binding domain, 13 or MB24, an antibody against the //-terminal domain of apo B (far removed from the LDL receptor-binding site), 14 further enhanced the rate of uptake of LDL aggregates. Uptake by way of the F c receptor was confirmed when it was shown that aggregated LDL § 2 is SI U a. complexed with Fab or F(ab') 2 fragments did not have enhanced uptake (Figures 3 and 4) . The complexes of intact antibody and LDL aggregates were internalized and, in particular, degraded more rapidly than the aggregates themselves (Figures 6, 7, and 9). As expected, that more rapid internalization and degradation had a greater effect on the rate of cholesterol esterification in the cells ( Figure 5 ). Further work is needed before the in vivo relevance of the mechanism described here can be assessed. It will be necessary to determine which receptors on the macrophages are indeed involved in uptake and degradation of LDL aggregates and modified forms of LDL aggregates in vivo. In situ hybridization studies suggest that the LDL receptor is downregulated in atherosclerotic lesions, as might be expected. 5 Therefore, the continuing uptake of LDL may depend on either the scavenger and/or the F c receptors, according to the mechanism described in this paper.
We have previously shown that modifications of LDL render it highly immunogenic 32 and in particular, we have demonstrated the immunogenicity of autologous oxidized LDL. 7 ' 8 Autoantibodies to epitopes of modified LDL have been demonstrated in the sera of human subjects and WHHL rabbits. 7 -9 " We have recently found an increased prevalence of antibodies to an epitope of oxidized LDL, malondialdehydelysine, in the sera of subjects with carotid atherosclerosis. 33 The relevance of the observations reported in this paper depends on the presence within the artery wall of immune complexes of LDL. We speculate that within the intima, LDL would undergo both aggregation and oxidation, resulting in the formation of oxidized-aggregated LDL. Recently, we have demonstrated the presence within the artery wall of immune complexes consisting of oxidized LDL and antibodies to epitopes of oxidized LDL, 3435 suggesting the possibility that their uptake by way of the F c receptor pathway could contribute to foam cell formation.
Griffith et al 15 and Klimov et al 29 Gisinger et al 30 demonstrated that when soluble and insoluble immune complexes of LDL were adsorbed to erythrocytes, they were avidly taken up by macrophages. Monoclonal antibodies bind to specific epitopes on the LDL particle and form soluble immune complexes. In our model studies, we used these monoclonal antibodies to prepare highly defined immune complexes of LDL.
We speculate that such immune complexes could exist in vivo. Further studies are needed to determine if the LDL aggregates present in the intima contain oxidized LDL and if autoantibodies against oxidized LDL are associated with such aggregates. Uptake of antibodyaggregated (modified) LDL complexes by macrophages not only could lead to enhanced macrophage accumulation of cholesterol but also could result in the crosslinking of F c receptors, which has been shown to trigger the release of pro-oxidants such as superoxide anion and hydrogen peroxide.
36
- 37 This in turn could lead to the generation of still more oxidized LDL. 313839 Furthermore, it has been reported that uptake of insoluble LDL-immune complexes by human monocyte-derived macrophages, while leading to increased intracellular cholesteryl ester accumulation, paradoxically led to enhanced LDL receptor activity.
30
- 40 All of these in vitro studies suggest that uptake of immune complexes containing LDL could significantly modify macrophage behavior and thereby influence the atherogenic process.
Further studies are needed to determine the consequences for the uptake of such immune complexes by macrophages and whether this indeed occurs in vivo.
